Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A rare case of locally advanced DNA mismatch-repair-deficient adenocarcinoma of the colon in a 16-year-old male treated with neoadjuvant immunotherapy and single-incision laparoscopic resection.
Zhang D, Muensterer O, Neumann J, Dorman K, Rassner M, Schmid I, Heinemann V. Zhang D, et al. Among authors: neumann j. Pediatr Blood Cancer. 2023 Nov;70(11):e30653. doi: 10.1002/pbc.30653. Epub 2023 Sep 5. Pediatr Blood Cancer. 2023. PMID: 37669240 No abstract available.
The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.
Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S. Modest DP, et al. Among authors: neumann j. Int J Cancer. 2012 Aug 15;131(4):980-6. doi: 10.1002/ijc.26467. Epub 2011 Nov 17. Int J Cancer. 2012. PMID: 21960311 Free article. Clinical Trial.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V. Stintzing S, et al. Among authors: neumann j. Ann Oncol. 2012 Jul;23(7):1693-9. doi: 10.1093/annonc/mdr571. Epub 2012 Jan 4. Ann Oncol. 2012. PMID: 22219013 Free article. Clinical Trial.
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V. Stintzing S, et al. Among authors: neumann j. Int J Cancer. 2013 Jan 1;132(1):236-45. doi: 10.1002/ijc.27654. Epub 2012 Jun 26. Int J Cancer. 2013. PMID: 22644776 Free article. Clinical Trial.
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V. Boeck S, et al. Among authors: neumann j. Br J Cancer. 2013 Feb 5;108(2):469-76. doi: 10.1038/bjc.2012.495. Epub 2012 Nov 20. Br J Cancer. 2013. PMID: 23169292 Free PMC article. Clinical Trial.
Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors.
Michl M, Thurmaier J, Schubert-Fritschle G, Wiedemann M, Laubender RP, Nüssler NC, Ruppert R, Kleeff J, Schepp W, Reuter C, Löhe F, Karthaus M, Neumann J, Kirchner T, Engel J, Heinemann V. Michl M, et al. Among authors: neumann j. Clin Colorectal Cancer. 2015 Dec;14(4):281-90. doi: 10.1016/j.clcc.2015.05.009. Epub 2015 Jun 6. Clin Colorectal Cancer. 2015. PMID: 26123495
1,728 results